促销时间表 Galapagos NV
先进的时间表
简单图表
关于公司 Galapagos NV
Galapagos NV, биотехнологическая компания, работающая на клинической стадии, обнаруживает, разрабатывает и продает различные низкомолекулярные лекарства. Его программы клинической стадии включают филготиниб, ингибитор JAK1, который находится на различных этапах клинических испытаний для лечения ревматоидного артрита, болезни Крона, язвенного колита, CD тонкой кишки, фистулизирующей CD, синдрома Шегрена, анкилозирующего спондилита, псориатического артрита, кожного красная волчанка, мембранозная нефропатия волчанки и увеит. 更多详情| IPO date | 2005-05-06 |
|---|---|
| ISIN | US36315X1019 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | eur |
| Сайт | https://www.glpg.com |
| Цена ао | 26.5 |
| 每日价格变化: | 0% (26.5) |
|---|---|
| 每周价格变化: | -0.7119% (26.69) |
| 每月价格变化: | +12.24% (23.61) |
| 3个月内价格变化: | -5.76% (28.12) |
| 六个月内的价格变化: | -7.89% (28.77) |
| 每年价格变化: | -24.52% (35.11) |
| 3年内价格变化: | -56.43% (60.82) |
| 5年内价格变化: | -90.33% (274.03) |
| 10年价格变化: | 0% (26.5) |
| 年初以来价格变化: | -0.5629% (26.65) |
|
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
|||||||||||||||||||||||||||||||||||||
| 机构 | 体积 | 分享, % |
|---|---|---|
| EcoR1 Capital, LLC | 5756268 | 8.74 |
| FMR, LLC | 4233803 | 6.42 |
| BVF Inc. | 1915109 | 2.91 |
| Segall Bryant & Hamill, LLC | 874728 | 1.33 |
| Prosight Management, LP | 827294 | 1.26 |
| PRIMECAP Management Company | 678877 | 1.03 |
| Deerfield Management Company, L.P. (Series C) | 622112 | 0.94 |
| Wellington Management Group, LLP | 495217 | 0.75 |
| Blackrock Inc. | 463260 | 0.7 |
| Finepoint Capital, LP | 458659 | 0.7 |
| ETF | 分享, % | 本年盈利能力, % | 股息, % |
|---|---|---|---|
| ProShares UltraShort Nasdaq Biotechnology | 0.22 | -40.36 | 1.76 |
| Schwab International Small-Cap Equity ETF | 0.06282 | 10.07 | 3.20638 |
| Invesco Nasdaq Biotechnology ETF | 0.05978 | 28.58 | 0.8565 |
| Future Tech ETF | 0.05876 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.05876 | 618.5 | 0.8416 |
| Invesco FTSE RAFI Developed Markets ex-U.S. Small-Mid ETF | 0.05192 | 2.77 | 3.5165 |
| ProShares Ultra Nasdaq Biotechnology | 0.04086 | 51.7 | 0.85651 |
| Goldman Sachs Innovate Equity ETF | 0.04041 | 29.66 | 1.20987 |
Vanguard FTSE All-World ex-US Small-Cap ETF
|
0.04 | 9.39 | 3.09932 |
| FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund | 0.0241 | 5.17 | 3.85434 |
| Xtrackers MSCI Eurozone Hedged Equity ETF | 0.0228 | 13.14 | 3.86046 |
| Avantis Responsible International Equity ETF | 0.02066 | 17.44 | 3.61591 |
| Avantis International Equity ETF | 0.01172 | 6.46 | 3.80856 |
| SPDR Portfolio Europe ETF | 0.00949 | 8.94 | 3.66537 |
SPDR Portfolio Developed World ex-US ETF
|
0.00506 | 5.29 | 3.28401 |
| Vanguard ESG International Stock ETF | 0 | 6.39 | 3.07501 |
| 导师 | 职称 | 支付 | 出生年份 |
|---|---|---|---|
| Ms. Sofie Van Gijsel | Head of Investor Relations | N/A | |
| Marieke Vermeersch | Head of Corporate Communication | N/A | |
| Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman, Interim Head of R&D | 974.86k | 1962 (63 年) |
| Ms. Valeria Cnossen | Executive VP & General Counsel | N/A | 1974 (51 年) |
| Ms. Annelies Missotten | Executive VP & Chief Human Resources Officer | N/A | 1973 (52 年) |
| Ms. Ellen Van Der Aar | Head of Development | N/A | |
| Mr. Dirk De Naeyer | Head of Development Operations | N/A | |
| Mr. Thad Huston | Executive VP, CFO & COO | N/A | 1971 (54 年) |
| Mr. Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Business Development | N/A | |
| Ms. Alice Dietrich | Head of Medical Affairs | N/A |
地址: Belgium, Mechelen, Generaal De Wittelaan L11 A3 - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.glpg.com
网站: https://www.glpg.com
